Advanced Enzyme Technologies Limited — Regulatory Filings 2021

Sep 13, 2021

September 13, 2021

BSE Limited Department of Corporate Affairs P. J. Towers, Dalal Street, Mumbai ‐ 400 001 Scrip ID‐540025

National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block Bandra‐Kurla Complex, Bandra (E) Mumbai ‐ 400 051 Scrip Code‐ADVENZYMES

Dear Sir/Madam,

Sub: Press Release

Please find enclosed copy of the Press Release dated September 13, 2021 and titled “Advanced Enzymes announces Positive Clinical Breakthrough in the Randomized Controlled Trials of Systemic Enzymes and Probiotics to Resolve ‘Long Covid’ Fatigue Symptoms”. Also attached are press release in Hindi, Marathi and Gujarati languages and the presentation.

In this regard, the Company has also scheduled the virtual press conference today.

Kindly take the above on record.

Thanking you,

Yours faithfully,

For Advanced Enzyme Technologies Limited

SANJAY Digitally signed by SANJAY PRAKASH PRAKASH BASANTAN BASANTANI Date: 2021.09.13 ____ I 10:51:17 +05'30'

Sanjay Basantani Company Secretary and Head – Legal

Encl.: As above

PRESS RELEASE

ADVANCED ENZYMES ANNOUNCES POSITIVE CLINICAL BREAKTHROUGH IN THE RANDOMIZED CONTROLLED TRIALS OF SYSTEMIC ENZYMES AND PROBIOTICS TO RESOLVE ‘LONG COVID’ FATIGUE SYMPTOMS

AETL has unleashed its Holy Grail regenerative systemic enzymes and probiotics supplements, which is incredibly effective for people suffering from ‘Post COVID’ fatigue symptoms.

HIGHLIGHTS:

• Randomized, multicentre, double blind and placebo‐controlled clinical trials were conducted on 200 patients suffering from post COVID fatigue symptoms.

• The clinical trials were conducted in two segments—around 100 patients (test arm) were administered with oral supplements for 14‐days, and rest 100 patients (control arm) were administered with placebo.

• The clinical efficacy was conducted as per the Chalder Fatigue Scale (CFQ‐11) for 14‐days.

• Clinical trials factored positive results in terms of resolution of fatigue in a greater proportion on patients during the test as against the control arm (91% vs. 15%).

• In August 2021, the company forayed into the E‐commerce space with its flagship all natural, chemical‐free COVID immunity management bundle — ‘ImmunoSEB’ and ‘Biome ULTRA’ in the US and Indian markets.

MUMBAI, SEPTEMBER 13, 2021: Advanced Enzyme Technologies Limited (AETL) ( NSE: ADVENZYMES; BSE: 540025 ) today announced that its systemic enzyme and probiotic supplements—ImmunoSEB and ProbioSEB CSC3 have passed the promising stages of randomized controlled clinical trials in terms of efficacy to resolve post‐COVID fatigue symptoms.

It’s a fact that muscle fatigue and cognitive disturbances persist in patients after recovery from acute COVID‐19 disease. However, there are no specific treatments available globally to treat post‐COVID fatigue complications.

With an aim to evaluate the efficacy and safety of the health supplements ImmunoSEB (systemic enzyme complex) and ProbioSEB CSC3 (probiotic complex) in patients suffering from COVID‐19 induced fatigue, a randomized, multi‐centric, double blind and placebo‐controlled trial was conducted in 200 patients suffering from post‐COVID fatigue symptoms.

The test arm (100 patients) received the oral supplements for 14‐days and the control arm (100 patients) received placebo, informed Dr. Abhijit K. Rathi, Principal Scientist, AETL.

The randomized clinical trial was conducted on 200 patients that did not have an active SARS‐CoV‐2 infection, as determined by a negative COVID‐19 test, with a complaint of post‐COVID fatigue. Patients were required to have a positive COVID‐19 test at any time in the past. The trial was conducted across three centres in India—Swasthya Hospital, Bhopal; Samvedna Hospital, Varanasi; and Chirayu Medical College & Hospital, Bhopal by Investigators for 14‐days, informed Dr Rathi.

According to the clinical research paper published by the Switzerland‐based “Medicines” Journal on August 30, 2021, the treatment efficacy was compared using the Chalder Fatigue Scale (CFQ‐11) for 14‐days. Interestingly, the supplemental treatment resulted in resolution of fatigue in a greater percentage in patients during the test as against the control arm (91% vs. 15%) during the 14‐day trial. Patients in the test arm category showed a significantly greater reduction the overall physical and mental fatigue scores as against patients in the control arm segment. The supplements were well tolerated with no adverse events reported. This clinical study demonstrated that the 14‐day supplementation of ImmunoSEB and ProbioSEB CSC3 resolved post‐COVID‐19 fatigue symptoms and improved patients’ functional status and quality of life, informed Dr. Rathi.

The Coronavirus disease‐19 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is a worldwide pandemic afflicting a large population across the globe. Most infected people develop acute symptoms that last for 7–10 days. However, one or more symptoms (physical, cognitive and/or psychological) persist for weeks or even months in a substantial percentage of people. Fatigue is the most persistent and debilitating symptom of long COVID.

Studies revealed that about 52 percent of patients among the studied population showed fatigue/myalgia post‐COVID‐19.

A survey done by the Office for National Statistics (ONS), United Kingdom suggests that about one in five people have symptoms of long COVID five weeks after an initial infection and one in ten after twelve weeks. The chronic phase of COVID‐19 is conjectured to be perpetual, with impaired functional status and quality of life. Though the data on COVID fatigue is still emerging, viral infections are known to trigger chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME) in patients. There are no specific biomarkers, and diagnosis is typically based on symptoms.

“Enzymes and probiotics are a robust mechanism to revitalize stamina and vitality, which is proved during the recently concluded randomized clinical trials,” said Mr. Vasant Rathi, Chairman, AETL.

“Recent trials suggest that nutraceuticals product supplement succours in recovery of COVID patients. However, the patient‐oriented outcome of the supplement may vary in individuals. For some, they may find a difference within couple of days, but for others, it may take a week or ten days. To avail long‐term benefit and better results of the supplement, it’s advisable to take the immunity bundle doses consistently every day for couple of months. However, in case you miss the dosage, don’t’ worry as it has no side effects,” said Mr. Rathi.

“We have served the Americans since over last 30 years. But during the pandemic, our key focus was to enhance immunity amongst Indians. Hence, we went online with our research‐backed immunity bundle. I feel, doctors need to address the issue of post‐COVID immunity soon as its affecting quality of life,” said Mr. Mukund Kabra, Director, Advanced Enzyme Technologies Limited (AET).

To benefit common people our researched‐backed chemical‐free post‐COVID immune support bundle — ImmunoSEB and Biome Ultra (ProbioSEB CSC3), our company has beefed up our omnichannel presence across India and globally. We tasted our runaway success in the US markets amidst the pandemic, hence decided to list our flagship immune support brands across online marketplaces in India to target a larger swath of pill‐fatigued, healthy agers, immunity conscious millennials, and Gen Z, said Mr Kabra.

Meanwhile, the products are currently available globally on the leading e‐commerce marketplace — Amazon. In a move to further shore up its direct‐to‐customer (D2C) omnichannel retailing business, AETL has unveil its online store — 'Advanced Enzymes e‐Direct Store' in September 2021 to help customers choose from a wide range of health support products.

ABOUT ADVANCED ENZYME TECHNOLOGIES LIMITED

Incorporated in 1989, Advanced Enzyme Technologies Limited (AET) is a research‐driven global company with leadership in manufacturing enzymes and probiotics. The company offers eco‐safe solutions to various industries, such as human health care & nutrition, animal nutrition, baking, fruit & vegetable processing, brewing & malting, grain processing, protein modification, dairy processing, specialty applications, textile processing, and to name a few.

The company aims to supplant traditionally used chemicals with eco‐friendly enzymatic solutions. It provides customized and effective enzyme solutions coupled with the best in technical advice and superior services. It has seven state‐of‐the‐art manufacturing units and six R&D located across India, Germany, and the US. It exports to over 45 countries spread across six continents.

On January 11, 2021, AET acquired a majority stake in SciTech Specialties specializing in effervescent‐based products for Rs.316 million. The acquisition synergized the company with two manufacturing facilities and one R&D facility. It led to a growth of 1.8 percent. Currently, the company has nine manufacturing units and seven R&D facilities.

FOR MORE INFORMATION, PLEASE CONTACT PRITTLE PRATTLE PR

Smruti Alinje Bhalerao I (+91) 96195 50143 I smruti@prittleprattle.in Vidyut Kumar Ta I (+91) 8879041399 I vidyut@prittleprattle.in

PRESS RELEASE

एडवांस एंजाइ�स ने लंबे समय से चल रहे को�वड के थका देने वाले ल�ण� के �नदान हेतु �म र�हत �नयं��त पर��ण� के �लए �णाल�गत तथा �ो�बयो�ट�स सकार�मक ि�ल�नकल खोज क� घोषणा क�

मुंबई, 13 �संतबर, 2021 : एडवांस एंजाइम टे�नोलॉिजस �लमीटेड (एइट�एल) (एनएसइ एडीवीइएनवायएमइएस ; बीएसइः 540025) ने आज उनके संपूण� और �ो�बयो�ट�स सि�लमे��स- इ�युनोसेब और �ो�बयोसेब सीएससी3 �वारा को�वड से उबरने के प�ताच होने वाल� लंबी थकान के ल�ण� के �नयं��त करने के �लए �भावका�रता के संदभ� म� �म र�हत �नयं��त नैदा�नक पर��ण� को आशाजनक तौर पर पार कर �लया।

एइट�एल के मु�य वै�ा�नक डा. अ�भजीत के राठ� �वारा को�वड-19 क� बीमार� से पी�ड़त हो चुके थके हुए 200 रो�गय� म� �वा��य पूरक इ�यूनोएसईबी (�स�ट�मक एंजाइम कॉ��ले�स) और �ो�बयोएसईबी सीएससी3 (�ोबायो�टक कॉ��ले�स) क� �भावका�रता और सुर�ा का मू�यांकन करने के उ�े�य से एक �म र�हत , बहु-क���त , दोहरे �लाइंड और �लेसीबो�नयं��त पर��ण क� जानकार� द� गई।

डा. राठ� �वारा द� गई जानकार� के अनुसार इन 200 रो�गय� क� भारत के तीन �वा��य क��� �वा��य अ�पताल, भोपाल, संवेदना अ�पताल, वाराणसी और �चरायु मे�डकल कॉलेज एंड अ�पताल, भोपाल म� 14 �दन� तक जांच क� गई।

ि�व�जरल�ड के नैदा�नक शोध प� "मे�ड�स�स" जन�ल �वारा 30 अग�त 2021 को �का�शत खबर के अनुसार इन रो�गय� का चा�डेर फॉ�तग �केल ( CFQ- 11) का उपयोग करके 14 �दन� तक उपचार के �भाव क� तुलना क� गई। डा. राठ� ने बताया �क �दलच�प बात यह हुई �क इस संपूण� उपचार के प�रणाम �व�प इन 14 �दन� पर��ण के दौरान रो�गय� म� थकान को (91% बनाम 15%) के बड़े अनुपात म� कम करने म� सफलता �मल�, जो �क काफ� उ�साहनवध�क है।

एईट�एल के अ�य� �ी वसंत राठ� ने कहा, "एंजाइम और �ोबायो�ट�स सहनशि�त और जीवन शि�त को पुनज��वत करने के �लए एक मजबूत तं� ह�, जो �क हाल ह� म� संप�न �म र�हत �वा��य पर��ण� के दौरान सा�बत हुआ है।"

“ उ�होन� आगे बताया �क हमारे शोध-सम�थ�त सभी �ाकृ�तक , रासाय�नक-मु�त को�वड के प�चात इ�यून बढ़ाने म� मददगार इ�यूनोएसईबी और बायोम अ��ा (�ो�बयोएसईबी सीएससी 3) जनता क� भलाई के �लए हमार� कंपनी ने पूरे भारत और �व�व �तर पर अपनी उपि�थ�त को दज� कराया है। यह उ�पाद अमेज़न पर उपल�ध है।

एईट�एल के पूण�का�लक �नदेशक �ी मुकुंद काबरा ने जानकार� द� �क महामार� के दौरान अमर�क� बाजार म� �मल� सफलता से उ�सा�हत हमार� कंपनी ने भारत म� ऑनलाईन माक�ट के सभी जगह� पर अपने उ�पादन ��तर�ा को बढ़ाने वाले �ांड� को सूचीब� करने का फैसला �कया है, जो �क अ�धकतर टैबलेट के सेवन से परेशान, �व�थ उ� को लोग�, �वा��य के ��त जाग�क नाग�रक और जेन जेड के लोग� को ल��त का करने का ल�य रखा गया है।

PRESS RELEASE

को�वडप�चात काळात द�घ�काल�न थकवा ल�णावर गुणकार� असले�या �स�टे�मक ए�झाई�स व �ोबायो�ट�स�या या��छ�क �नयं��त चाच�यांना सकारा�मक वै�य�कय ��तसाद �मळा�याची ‘अॅड�हा�स� ए�झाई�स’ची घोषणा

मबई, १३ स�टबर २०२१ : अॅड�हा�स� ए�झाईम टे�नॉलॉजीज �ल�मटेड (एईट�एल) (एनएसई: ADVENZYMES बीएसई : 540025 ) ने आज आप�या ‘इ�यूनोएसईबी’ आ�ण ‘�ोबायोएसईबी सीएससी३’ या �स�टे�मक ए�झाईम व �ोबायोट�क स�ल�म�टनी या��छ�क �नयं�ण वै�यक�य चाच�यांची मह�वपूण� पायर� पूण� के�याचे जाह�र केले आहे. या चाच�या ��णांमधील को�वडप��यात जी तणाव ल�णे आढळतात �यावर�ल �भावा�या संदभा�तील आहेत.

को�वड-१९मुळे �या ��णांम�ये थकवा जाणवतो �यां�यामधील ‘इ�यूनोएसईबी’ (सी�टे�मक ए�झाईम कॉ��ले�स) आ�ण ‘�ोबायोएसईबी सीएससी3’ (�ोबायोट�क कॉ��ले�स) या पूरक औषधांची प�रणामकारकता आ�ण सुर��तता तपास�यासाठ� ह� चाचणी केल� गेल�. ह� चाचणी या��छ�क, बहुके���, दुपेडी आ�ण �लॅसीडो �नयं��त होती आ�ण ती �या ��णांम�ये को�वडनंतर थकवा अनुभवायला येत होता, अशा २०० ��णांम�ये केल� गेल�, अशी मा�हती ‘एईट�एल’चे �मुख शा��� डॉ अ�भिजत के राठ� यांनी �दल�.

देशभरातील �वा��य ��णालय, भोपाळ; संवेदना ��णालय, वाराणसी आ�ण �चरायू मे�डकल कॉलेज व ��णालय, भोपाळ या तीन �ठकाणी २०० ��णांवर ह� चाचणी केल� गेल�. ह� चाचणी शा���ांकडून १४ �दवस केल� गेल�, असे ह� डॉ राठ� �हणाले.

ि�व�झल�डि�थत ‘मेडी�स�स’ या जन�लने ३० ऑग�ट २०२१ रोजी जो एक वै�यक�य संशोधन �बंध �का�शत केला आहे, �यानुसार उपचारांची प�रणामकारकता ह� ‘चा�डर फ�टग �केल’ (सीएफ�यू ११) वाप�न केल� गेल� होती आ�ण ती १४ �दवस वापरल� गेल� होती. �वशेष �हणजे, १४ �दवसां�या या काळात ‘ कं�ोल आम� ’ शी ( संबं�धत औषधे�वर�हत कालावधी ) तुलना करता या पूरक औषधोपचारांचा प�रणाम असा झाला क� ��णांमधील थकवा हा चाचणीदर�यान मो�या �माणावर कमी (९१% �व�� १५%) झाला, असेह� डॉ राठ� यांनी �हटले आहे.

ए�झाईम व �ोबायो�ट�स ह� आपल� श�ती व चेतना बलशाल� कर�याची एक भ�कम यं�णा आहे आ�ण ह� बाब नुक�याच �या या��छ�क चाच�या के�या गे�या �यातून �स� झाले आहे, असे उ�गार ‘एईट�एल’चे अ�य� �ी वसंत राठ� यांनी काढले आहेत.

“संपूण�तः नैस�ग�क, संशोधनाचे भ�कम पाठबळ असलेल� रसायनमु�त को�वड-प��यात रोग��तकारक औषधे ‘इ�युनोएसईबी’ आ�ण ‘बायोमीअ��ा’ (�ोबायोएसईबी सीएससी3) लोकां�या �हतासाठ� कंपनीने संपूण� भारत आ�ण जाग�तक �तरावर�ल आम�या सव�समावेशक अि�त��वावर भर �दला आहे. ह� उ�पादने भारतात अॅमॅझॉनवर उपल�ध आहेत.

साथरोगा�या काळात आ�ह� अमे�रकेम�ये आम�या यशाची चाचणी केल� आ�ण आ�ण �यानंतर आ�ह� आमचे �मुख रोग��तकारकश�ती वाढ�वणारे �ँड भारतात ऑनलाईन बाजारपेठेत आणायचे ठरवले. �या�वारे आ�ह� गो�यांचा कंटाळा आलेले, सु�ढ वयोवृ�, रोग��तकारक श�तीब�ल जाग�क असलेले �वशीतील त�ण या मो�या वयोगटाला समोर ठेवून ह� उ�पादने दाखल केल� गेल� आहेत,” असे उ�गार ‘एईट�एल’चे साव�का�लक संचालक �ी मुकुंद का�ा यांनी काढले.

PRESS RELEASE

એડવા�સ એ�ઝાઈ�સ �ારા કોિવડ પ�ાતનાં થાકનાં લ�ણોનો ઉક�લ લાવવા માટ� િસ�ટિમક એ�ઝાઈ�સ અને �ોબાયો�ટ�સના અડસ�� િનયંિ�ત પર��ણોમાં હકારા�મક �ચ�ક�સક�ય �ગિતની ઘોષણા

�બઈ, 13 સું �ટ બર, 2021- એડવા��ડ એ�ઝાઈમ ટ�કનોલો�ઝ �લિમટ�ડ (એઈટ�એલ) ( NSE: ADVENZYMES; BSE: 540025 ) �ારા આ� તેનાં િસ�ટિમક એ�ઝાઈમ અને �ોબાયો�ટક �ૂરકો- ઈ��ુનો એસઈબી અને �ોબાયોએસઈબી સીએસસી3 �ારા કોિવડ પ�ાત થાકનાં લ�ણોનો ઉક�લ લાવવા માટ� કાય�સાધકતાની દ��ટએ અડસ�� િનયંિ�ત �ચ�ક�સક�ય પર��ણોનો આશા�પદ તબ�ો પસાર કય� હોવાની આ� ઘોષણા કર� હતી.

કોિવડ-19 �ે�રત થાકથી પીડાતા દદ�ઓમાં આરો�યનાં �ૂરકો ઈ��ુનો એસઈબી (િસ�ટિમક એ�ઝાઈમ કો��લે�સ) અને �ોબાયોએસઈબી સીએસસી3 (�ોબાયો�ટક કો��લે�સ)ની કાય�સાધકતા અને �ુર�ા�ું �ૂ�યાંકન કરવાના લ�ય સાથે અડસ��, બ�ુક ��ત, ડબલ �લાઈ�ડ અને �લાસીબો- િનયંિ�ત પર��ણ કોિવડ પ�ાત થાકનાં લ�ણોથી પીડાતા 200 દદ�ઓમા હાથ ધરા�ું હ�ું, એમ એઈટ�એલના �ુ�ય િવ�ાની ડો. અ�ભ�જત ક� રાઠ�એ જણા��ું હ�ું.

આ અડસ�� �ચ�ક�સક�ય પર��ણ ભારતમાં �ણ ક �ોમાં 200 દદ�ઓ પર 14 �દવસો માટ� તપાસકતા�ઓ �ારા હાથ ધરા�ું હ�ું, �માં �વા��ય હો��પટલ- ભોપાલ, સંવેદના હો��પટલ- વારાણસી અને �ચરા�ુ મે�ડકલ કોલેજ એ�ડ હો��પટલ, ભોપાલનો સમાવેશ થતો હતો.

30 ઓગ�ટ, 2021ના રોજ ��વટઝલ ડ ��થત મે�ડસી�સ જન�લ �ારા �િસ� �ચ�ક�સક�ય સંશોધન પેપર અ�ુસાર ઉપચારની કાય�સાધકતાની �ુલના 14 �દવસ માટ� ચે�ડર ફ ટગ �ક�લ (સીએફ�ુ- 11)નો ઉપયોગ કર�ને �ુલના કરવામાં આવી હતી. રસ�દ ર�તે 14 �દવસના િનયં�ણ પાંખ (91 ટકા સામે 15 ટકા) સામે પર��ણ દરિમયાન દદ�ઓમાં વ�ુ ટકાવાર�માં થાકનો ઉક�લ લાવવામાં �ૂરક ઉપચાર પ�રણ�યો હતો, એમ ડો. રાઠ�એ જણા��ું હ�ું.

એ�ઝાઈ�સ અને �ોબાયો�ટ�સ �ટ�િમના અને િવટા�લટ� �ુનજ�િવત કરવા માટ� મજ�ૂત યં�ણા છે, � તા�તરમાં �ૂણા થયેલાં અડસ�� �ચ�ક�સક�ય પર��ણો દરિમયાન િસ� થયાં છે, એમ એઈટ�એલના ચેરમેન �ી વસંત રાઠ�એ જણા��ું હ�ું.

અમારા સંશોધન આધા�રત સવ� નૈસ�ગ�ક, રસાયણ �ુ�ત કોિવડ પ�ાર ઈ��ુન સપોટ� બંડલ ઈ��ુનોએસઈબી અને બાયોમી અ��ા (�ોબાયોએસઈબી સીએસસી3) લોકોના �હત માટ� અમાર� કંપનીએ ભારત અને �ુિનયાભરમાં અમાર� ઓ�નીચેનલ હાજર� વધાર� દ�ધી હતી. અમે મહામાર� વ�ચે �ુએસ બ�રમાં અમાર� સફળતાને ચાખી છે, આ �ોડ�ટ એમેઝોન પર ઉપલ�ધ છે .

�થી ગોળ�થી કંટાળેલા, આરો�યવધ�ક �ુ�તો, ઈ��ુિનટ� સતક� નવી પેઢ� અને જન ઝેડના મોટા વગ�ને �યાનમાં રાખીને ભારતમાં ઓનલાઈન માક�ટ�લેસમાં �ા��સને ટ�કો આપવા માટ� અમાર� �લેગિશપ ઈ��ુન સપોટ� આપવા�ું ન�� ક�ુ� છે, એમ એઈટ�એલના હોલ ટાઈમ ડાયર ટર �ી �ુ�ુંદ કા�ાએ જણા��ું હ�ું.

==> picture [792 x 223] intentionally omitted <==

SEPTEMBER 13, 2021 Advanced Enzyme Technologies Limited

SAFE HARBOUR STATEMENT

This presentation contains forward-looking statements that reflect management’s current views with respect to certain future events and potential financial performance. Forward-looking statements are other than statements of historical facts. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “outlook,” “will,” “may,” “continue,” “should” and similar expressions identify forward-looking statements.

Forward-looking statements include statements regarding objectives, goals, strategies, outlook and growth prospects; future plans, events or performance and potential for future growth; liquidity, capital resources and capital expenditures; economic outlook and industry trends; developments of the Company’s markets; the impact of regulatory initiatives; and the strength of competitors. The forwardlooking statements in this presentation are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, management’s examination of historical operating trends, data contained in records and other data available from third parties.

Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and maybe beyond our control. Such risks, uncertainties, contingencies and other important factors could cause the actual results of the Company or the industry to differ materially from those results expressed or implied in this presentation by such forward-looking statements.

The information, opinions and forward-looking statements contained in this presentation speak only as at the date of this presentation and are subject to change without notice. The Company and its respective agents, employees or advisors do not intend to, and expressly disclaim any duty, undertaking or obligation to, make or disseminate any supplement, amendment, update or revision to any of the information, opinions or forward-looking statements contained in this presentation to reflect any change in events, conditions or circumstances beyond what is required by applicable law or applicable stock exchange rules and regulations.

By viewing this presentation, you acknowledge and agree to be bound by the foregoing limitations and restrictions.

Earnings Presentation | Q1 FY22

2

POST VIRAL FATIGUE

AN EXTENDED PERIOD OF FEELING UNWELL AND FATIGUED AFTER A VIRAL INFECTION

The survey done by an Office for National Statistics (ONS) United Kingdom suggests that about one in five people have symptoms of long COVID five weeks after an initial infection and one in ten after 12 weeks[1] .

==> picture [792 x 320] intentionally omitted <==

----- Start of picture text -----

Tiredness or Fatigue
Joint or Muscle pain
Difficulty in concentrating (Brain Fog)
Difficulty in breathing
Difficulty in thinking and concentrating
Diarrhea
Many other symptoms…
1. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/alldatarelatingtoprevalenceofongoingsymptomsfollowingcoronaviruscov
id19infectionintheuk
2. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/media-resources/science-in-5/episode-47---post-covid-19- Earnings Presentation | Q1 FY22 3
condition?gclid=CjwKCAjwyvaJBhBpEiwA8d38vMtvc_021k7od5B88oMvGRnRJoeUoYLUQpk2CWJSks_eqWQVOXDQaRoCBoIQAvD_BwE
----- End of picture text -----

RANDOMIZED CONTROLLED TRIAL OF THE EFFICACY OF SYSTEMIC ENZYMES AND PROBIOTICS IN THE RESOLUTION OF POST-COVID FATIGUE

==> picture [160 x 175] intentionally omitted <==

==> picture [159 x 175] intentionally omitted <==

==> picture [159 x 175] intentionally omitted <==

OBJECTIVE

Objective: To evaluate the efficacy and safety of the health supplements ImmunoSEB and ProbioSEB CSC3 in patients suffering from COVID‐19 induced fatigue,a randomized, multicentric, double blind, placebo‐controlled trial was conducted in 200 patients with a complaint of post‐COVID fatigue.

Earnings Presentation | Q1 FY22

CLINICAL TRIAL

The test arm (n = 100) received the oral supplements for 14 days and the control arm (n = 100) received a placebo. Treatment efficacy was compared using the Chalder Fatigue scale (CFQ‐11), at various time points from days 1 to 14. The supplemental treatment resulted in resolution of fatigue in a greater percentage of subjects in the test vs. the control arm (91% vs. 15%) on day 14.

4

OUTCOME

Subjects in the test arm showed a significantly greater reduction in total as well as physical and mental fatigue scores at all time points vs. the control arm. The supplements were well tolerated with no adverse events reported. This study demonstrates that a 14 days supplementation of ImmunoSEB + ProbioSEB CSC3 resolves post‐COVID‐19 fatigue and can improve patients’ functional status and quality of life.

A 200 patients Clinical study: On post COVID fatigue

==> picture [792 x 150] intentionally omitted <==

Clinically validated product that helps post COVID / viral fatigue

Earnings Presentation | Q1 FY22

5

A 200 patients clinical study conducted in July 2021 on post COVID fatigue

==> picture [792 x 150] intentionally omitted <==

Earnings Presentation | Q1 FY22

==> picture [6 x 7] intentionally omitted <==

----- Start of picture text -----

6
----- End of picture text -----

IT’S PURELY A SUPPLEMENTAL THERAPY AND NOT A “DRUG”

RESEARCHED-BACKED ALL NATURAL, CHEMICAL-FREE POST-COVID IMMUNE SUPPORT SUPPLEMENTS

ImmunoSEB (systemic enzyme complex) and ProbioSEB CSC3 (probiotic complex)

==> picture [792 x 150] intentionally omitted <==

----- Start of picture text -----

•
----- End of picture text -----

ImmunoSEB + ProbioSEB CSC3 was clinically found to be efficacious as supplemental therapy administered in mild‐to‐moderate COVID‐19 patients as it indicated overall clinical improvement as per WHO 7‐point ordinal scale

Earnings Presentation | Q1 FY22

7

==> picture [694 x 409] intentionally omitted <==

----- Start of picture text -----

Clinical study: On mild to moderate COVID-19 hospitalized patients
Results Summary – Q1 FY22 (Consolidated) Y-o-Y
Days to clinical improvement, fever reduction and hospitalization days
Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn)
Clinical trial was conducted on 60 patients in October 2020
Days to clinical improvement Days of hospitalization Time to normalization of Fever without
use of Antipyretics in last 24 hours
8.56 1,370 7.83 628 399
7.8
348
517
1,105
9.6 8.76 8.6
7 8 9 10 11 7 8 9 10 7 7.5 8 8.5 9 9.5
Days Days Days
Q1 FY21 Q1 FY22 C‐Reacti ve Protein (CRP) and SPO Q1 FY21 Q1 FY22 2 Leve ls Q1 FY21 Q1 FY22
CRP Level Mean Improvement in SpO2 Levels
25
1.05
Despite trailing impact of COVID -19 and panic across globe, we performed exceptionally well and that is quantified below.20 18.401 1
• Revenue grew by 24% on y-o-y basis to ₹ 1,370 million in the Q1 FY22 from ₹ 1,105 million in the Q1 FY21 and 3% on sequential basis from 0.95 0.9233 ₹ 1,332 million in the
Q4 FY21 14.722 0.9
15
• EBITDA grew by 21% to ₹ 628 million in the Q1 FY22 as against 11.8527 ₹ 517 million in Q1 FY21 on y-o-y basis and 14% on sequential basis from 0.85 ₹ 549 million in the Q4
FY21 9.4023 0.8
10 0.7367
• PAT increased to ₹ 399 million in the Q1 FY22 from 6.5383 ₹ 348 million in the Q1 FY21, a growth of 15% on y-o-y basis while it grew by 18% on sequential basis from 0.75 ₹
338 million in Q1 FY21 4.21 5.3395.8207 0.7
5
• EBITDA margin and PAT margin during Q1 FY22 stands at 46% and 29% respectively0.65
0.6
Notes: 0 Standard of Care ImmunoSeb + Probiotic
1.On Consolidated BasisScreening Day Day 03 Day 07 Discharge Day
2.PAT is before minority Treatment Groups
3.Ind AS adjustments are carried out on account of commission, discount. And provision for sales return Standard of Care ImmunoSeb + Probiotic
Earnings Presentation | Q1 FY22 8
CSC3 CSC3
ProbioSEB ImmunoSEB + ProbioSEB ImmunoSEB + ProbioSEB CSC3
ImmunoSEB +
care care care
Standard of Standard of Standard of
(%)
Mean CRP (mg/l) Mean Improvement
----- End of picture text -----*

Shah N. et. al., Potential of the Combination of a Systemic Enzyme Complex and Probiotics administration to Combat COVID-19: A Randomized Open Label Prospective Analysis, Advanced in clinical Toxicology, 6,(1), 2021.

A case series: On post COVID-19 fatigue

Mean CFQ‐11 Scores During Treatment*

==> picture [429 x 328] intentionally omitted <==

----- Start of picture text -----

30 26.63
25.13
25
20 17.13
15 12.88
10 7.63
4.38
5 2.75
0
Baseline Day 3 Day 5 Day 7 Day 10 Day 12 Day 14
Mean SpO2 Levels During Treatment
100
99
98
97.75
98 97.375
96.875
97
96.125
96
95.25
95
94.125
94
93
Day 1 Day 3 Day 5 Day 7 Day 10 Day 12 Day 14
Earnings Presentation | Q1 FY22 9
MEAN SCORE
SPO2 LEVEL
----- End of picture text -----

==> picture [225 x 250] intentionally omitted <==

Parate R and Shah N. Management of Post COVID-19 Fatigue using Systemic Enzymes and Probiotics- Case Series. Med J Clin Trials Case Stud, 5(2), 2021.

Effective supplementation therapy…

==> picture [792 x 150] intentionally omitted <==

----- Start of picture text -----

Reduction of Hospitalization Time
Improved blood oxygen saturation
Faster resolution of fever
----- End of picture text -----

• *For use as dietary supplementation only

• Shah N. et. al., Potential of the Combination of a Systemic Enzyme Complex and Probiotics administration to Combat COVID-19: A Randomized Open Label Prospective Analysis, Earnings Presentation | Q1 FY22 10

Advanced in clinical Toxicology, 6,(1), 2021.

1. Parate R and Shah N. Management of Post COVID-19 Fatigue using Systemic Enzymes and Probiotics- Case Series. Med J Clin Trials Case Stud, 5(2), 2021.

Other Health Studies and Publications

CLINICAL TRIALS

Maity, C., and Gupta, A. K.(2021). Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome A prospective, interventional, randomized, double-blind, placebo-controlled clinical study [CONSORT Compliant]. Medicine (2021) 100:3. https://doi.org/ 10.1097/MD.0000000000023641

Maity, C., & Gupta, A. K. (2018). A prospective, interventional, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of Bacillus coagulans LBSC in the treatment of acute diarrhea with abdominal discomfort. European Journal of Clinical Pharmacology , 75 (1), 21–31. https://doi.org/10.1007/s00228-018-2562-x

Maity, C., Gupta, A. K., Saroj, D. B., Biyani, A., Bagkar, P., Kulkarni, J., and Dixit, Y. (2020). Impact of a gastrointestinal stable probiotic supplement Bacillus Coagulans LBSC on human gut microbiome. Journal of Dietary supplements. https://doi.org/10.1080/19390211.2020.1814931

Maity, C., and Gupta, A. K.(2021). A Prospective, Interventional, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of Bacillus clausii 088AE as Immunomodulator in Acute Allergic Rhinitis. CTRI/2020/09/027657 [Registered on: 08 Sep 2020] Mendeley Data, V1, doi: 10.17632/r28yk274z6.1

Maity, C., and Gupta, A. K.(2021). A Prospective Clinical Study to Evaluate the Efficacy and Safety of a Probiotic Combination of Bacillus clausii 088AE, Bacillus coagulans LBSC and Bacillus subtilis PLSSC as Immunomodulators in Acute Allergic Rhinitis. CTRI/2020/09/027657 [Registered on: 08 Sep 2020] Mendeley Data, V1, doi: 10.17632/dxx7czctmx.1

Maity, C., and Gupta, A. K.(2021). A Prospective, Interventional, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of ImmunoSEB as Immunomodulator in Acute Allergic Rhinitis, CTRI/2020/09/027657 [Registered on: 08 Sep 2020]. Mendeley Data, V1, doi: 10.17632/9c582b7rv3.1

Other Studies

Maity, C., Bagkar, P., Dixit, Y., Tiwari, A., & Gupta, A. K. (2020). Process and Storage Stability of Bacillus coagulans LBSC in Food Matrices and Appraisal of Calorific Restriction: B. coagulans LBSC stability and calorie restriction. Applied Food Biotechnology , 8 (1), 57-69. https://doi.org/10.22037/afb.v8i1.31212 Bagkar, P., Gupta, A., and Maity, C., (2021). Effect of high pressure processing (HPP) on spore preparation of probiotic Bacillus coagulans LBSC [DSM 17654] International Journal of Food Engineering, 000010151520200336. https://doi.org/10.1515/ijfe-2020-0336

Saroj, D. B., & Gupta, A. K. (2020). Genome based safety assessment for Bacillus coagulans strain LBSC (DSM 17654) for probiotic application. International Journal of Food Microbiology, 318,108523. https://doi.org/10.1016/j.ijfoodmicro.2020.108523

Earnings Presentation | Q1 FY22

11

The Immunity Bundle

7 Days Pack

15 Days Pack

==> picture [792 x 150] intentionally omitted <==

Available on

Earnings Presentation | Q1 FY22

12